1108658-10-1Relevant articles and documents
Hepatitis C virus inhibitors
-
, (2017/01/23)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease
Alexandre, Fran?ois-René,Brandt, Guillaume,Caillet, Catherine,Chaves, Dominique,Convard, Thierry,Derock, Michel,Gloux, Damien,Griffon, Yann,Lallos, Lisa,Leroy, Frédéric,Liuzzi, Michel,Loi, Anna-Giulia,Moulat, Laure,Musiu, Chiara,Parsy, Christophe,Rahali, Houcine,Roques, Virginie,Seifer, Maria,Standring, David,Surleraux, Dominique
, p. 3984 - 3991 (2015/08/24)
Abstract We disclose here the synthesis of a series of macrocyclic HCV protease inhibitors, where the homoserine linked together the quinoline P2′ motif and the macrocyclic moiety. These compounds exhibit potent inhibitory activity against HCV NS3/4A protease and replicon cell based assay. Their enzymatic and antiviral activities are modulated by substitutions on the quinoline P2′ at position 8 by methyl and halogens and by small heterocycles at position 2. The in vitro structure activity relationship (SAR) studies and in vivo pharmacokinetic (PK) evaluations of selected compounds are described herein.
MACROCYCLIC SERINE PROTEASE INHIBITORS
-
Page/Page column 109, (2009/03/07)
Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
